Psychedelics
September 8, 2026
Hongyuan Li, Xiaohui Wang
Central nervous system (CNS) injuries remain challenging to treat due to limited neurogenesis, inhibitory extracellular environments, and maladaptive neuroimmune responses. Psychedelic compounds, including classical serotonergic psychedelics, dissociative anesthetics, and empathogens, have re-emerged as mechanistically distinctive “psychoplastogens” capable of rapidly and persistently enhancing...
Psychedelics
August 15, 2026
Khaleel Rajwani
Recent interdisciplinary scholarship has demonstrated how systemic racism, racialized mental health disparities, and histories of colonial and biomedical violence shape psychedelic experiences, therapeutic outcomes, and processes of integration. Emerging literature has foregrounded concerns including racial underrepresentation in research, the violent legacy of the War on Drugs, systemic racism...
Psychedelics
August 14, 2026
Robert McGrath, Everett B. Sackett
Artificial intelligence is entering psychedelic-assisted therapy (PaT) through at least two channels, pre-licensure facilitator training simulators and in-session administrative tools. This arrival is occurring in a context where relational factors, those interpersonal considerations between patients and providers, are not incidental but highly impactful. A 2025 international Delphi consensus...
Psychedelics
August 13, 2026
Stephanie R. Rodriguez, PSS Daniel Friedrich, Kim Hoffman et al.
Psychedelics have been researched for decades, yet clinical investigations represent only a small fraction of their use. Some states have launched supervised psychedelic wellness services, outpacing controlled trials in the numbers of participants served. Veterans are key advocates for legal therapeutic access to psychedelics, seeking options through grassroots veteran-run organizations that...
Psychedelics
July 18, 2026
Sergio Pérez Rosal, Sonya C. Faber
Background In natural product psilocybin retreats, "dose" is commonly defined by grams of dried mushrooms, despite substantial batch-to-batch variability in psilocybin content. This limits safety predictability and undermines reproducibility and between-study comparability. We report an observational field evaluation of an existing, ICH Q2(R1)-validated rapid colorimetric/photometric assay...
Psychedelics
July 1, 2026
Aragorn Eloff, Alessandro Gonçalves Campolina
In this paper, which is in part intended as a speculative provocation and which combines philosophy of science, clinical practice and psychedelic therapy in a novel manner, we examine ketamine-assisted psychotherapy (KAP) through the lens of an expanded model of enactive cognition. While much work within both KAP and psychedelic-assisted therapy (PAT) in general has relied upon broadly...
Psychedelics
July 1, 2026
Etienne Artru
The psychedelic renaissance has now lasted longer than the first wave of medical research in the 1950s and 60 s. Despite growing scientific and cultural interest, fundamental questions remain regarding the nature of subjective experience and its role in therapeutic outcomes. This article revisits a neglected yet significant aspect of psychedelic phenomenology: birth—or rebirth—experiences....
Psychedelics
July 1, 2026
Nicholas Vucak, Raimondo Bruno, Julio Quealy et al.
Background Integration — the ongoing process of revisiting, making sense of, and incorporating the content of a psychedelic experience into daily life — is a core component of psychedelic-assisted therapy (PAT), but is variably operationalised and poorly reported in clinical research. Objective To map how integration is described, delivered, and reported in clinical studies of classic...
Psychedelics
July 1, 2026
Stacy Rush
Despite promising outcomes for mental health conditions, psychedelic-assisted interventions yield variable post-experience outcomes. Existing preparation and integration models emphasize insight and meaning-making but give insufficient attention to the role of internal guidance in sustaining therapeutic gains. For individuals shaped by trauma or performance-based environments, emotional...
Psychedelics
July 1, 2026
Sergio Pérez Rosal, Sonya C. Faber, M. Myriah MacIntyre et al.
Background Racism and discrimination are pervasive social determinants of health, yet mainstream mental health care often fails to address the psychological sequelae of racial trauma, or race-based traumatic stress (RBTS). While psychedelic-assisted therapy (PAT) has re-entered the scientific mainstream, empirical guidance for culturally attuned, integrative care is limited. This study explores...
Psychedelics
June 28, 2026
Joost J. Breeksema, Ulf Bremberg, Jens H van Dalfsen et al.
The research, understanding, and implementation of psychedelic therapies is characterised by a layered complexity that arises from the dynamic interactions between pharmacological and extra-pharmacological factors, and the embeddedness of psychedelics within broader societal, legal, and regulatory systems ill-equipped to accommodate them. This complexity is compounded by an epistemic...
Psychedelics
June 24, 2026
Oliver Davis
This article liberates discussion of the politics of psychedelics from its present impasse. Across ten theses, it asserts that psychedelics are interruptive deautomating political technologies, which makes them conducive to democratic politics, in the radical sense: rather than consolidating liberal-democratic systems of representative or managed democracy, psychedelic experience tends to open...
Psychedelics
May 30, 2026
Vinicius Ryu Kami, Beatriz Borges Bueno Salle, Giovanni Porto et al.
Background Contemporary psychiatry is associated with several challenges, including limited remission rates in complex and severe psychiatric disorders. In this context, psychedelics have re-emerged globally as a promising therapeutic paradigm. Brazil occupies a unique position in this scenario, mainly due to the legal protection and cultural integration of Ayahuasca, which fosters a distinct...
Psychedelics
May 16, 2026
Tam Martin Fowles, Tehseen Noorani
We take a wide view across the emerging research into psychedelics and psychosis/madness, to emphasize the need for not just more but also wise research at these intersections. We note the growing rate of publications on the use of psychedelics by people who have had experiences of psychosis/madness, and make our arguments around a narrative report of the lead author, who experienced a...
Psychedelics
May 16, 2026
Nádia Valéria Moreira Santos, Cristiane Ferreira Silveira, Camila Gutieres Dos Santos Soares Costa et al.
Aim This study aimed to explore the experiences and perceived effects of ayahuasca ceremonies on suicidality. Method We conducted in-depth qualitative interviews with nine participants from the North and Southeast regions of Brazil. These participants were part of a larger cohort and were selected to explore their perspectives on how ceremonial experiences with ayahuasca in neoshamanic contexts...
Psychedelics
May 14, 2026
Joseph T. la Torre, Jade Gallo, Matteo Buonaroti et al.
This paper presents qualitative data reported by individuals with histories of psychotic symptoms and experiences who engaged in naturalistic psychedelic use compiled as a case series. Through detailed first-person narratives, we explore how both classic and non-classic psychedelic experiences were subjectively experienced and integrated by individuals in this population, which is usually...
Psychedelics
May 1, 2026
Madeleine Cluck, Alison B. Purcell, Zuzana Kazan et al.
There is currently an ongoing resurgence in research on the therapeutic potential of psychedelics for psychiatric conditions. Psychedelic-assisted therapy (PAT) differs from most current forms of psychiatric treatment in two primary domains: its requirement for fewer doses (often just one), and its documented ability to promote profound insights, introspection, and cognitive shifts. Autism...
Psychedelics
April 25, 2026
Juliet Meccia, David Casimir, Sisi Li et al.
Over the past 25 years, the use of 5-MeO-DMT in informal and underground settings has contributed a substantial, yet underrecognized, body of knowledge relating to the efficacy of 5-MeO-DMT in alleviating depressive symptoms. Traditional models of drug development, typically characterized by structured trials and regulatory milestones, rarely consider findings from these alternative routes. The...
Psychedelics
April 20, 2026
Sophia M. Castillo, Noelle Cataldo, Cody J. Wenthur
Despite the existence of current treatments for major depressive disorder (MDD), depression symptoms and burdens often persist, prompting the need for novel therapies, including psychedelic-assisted therapy (PAT), with promising potential for early and durable antidepressant responses. Objectives: This research aims to compare pharmacist opinions regarding logistical and ethical considerations...
Psychedelics
April 20, 2026
José Carlos Bouso, Óscar Andión, Jordi Cantillo et al.
The Symmetrical Global Mental Health (Sym-GMH) paradigm proposes a reciprocal integration between traditional and Western medical systems. This prospective, longitudinal study evaluates the psychological outcomes of 264 Western participants who engaged in Shipibo-led ayahuasca retreats at the Temple of the Way of Light in the Peruvian Amazon. Over a 12-month period, participants completed...
Psychedelics
April 4, 2026
Nicholas Sawers, Michael Billingsley, David B Menkes
Psychiatric symptoms and existential distress are common at the end of life and associated with poor outcomes. Psychedelic therapies are an emerging option for managing such patients, but their testing and application depends, inter alia , on prescribers’ perspectives. However, no published data exist on the opinions of Australasian palliative care medical staff regarding psychedelic safety and...
Psychedelics
April 2, 2026
Dalia N. Balsamo, Prachi Garodia, Nima Fayazmanesh et al.
The integration of music into psychedelic-assisted therapy (PAT) has emerged as a key aspect of therapeutic psychedelic experiences, providing a significant enhancement in emotional processing and insight generation. This review examines the interplay between music and psychedelics, and explores how this integration can enhance therapeutic outcomes in various conditions with a broader emphasis...
Psychedelics
March 7, 2026
Glauber Loures de Assis, Adana Omágua Kambeba, Jairo Lima et al.
1 citation
The global psychedelic field has been narrated through the metaphor of a “Psychedelic Renaissance.” While effective in mobilizing public interest, this framing reproduces Eurocentric histories, Darwinian narratives of sociocultural progress, and biomedical logics that marginalize Indigenous sciences and relational ecologies. Enduring coloniality and conflicts concerning biomedicalization,...
Psychedelics
March 7, 2026
Skylar J. Gaughan, Jae Sevelius, Rafael Lancelotta et al.
Psychedelics have long histories of use in Indigenous communities for healing, spiritual, and ceremonial purposes. In contrast, Western psychedelic science has emerged through frameworks shaped by colonization, racism, and medicalization. These systems often marginalize and exclude the very communities most impacted by trauma, including transgender and gender-expansive (TGE) individuals,...
Psychedelics
March 1, 2026
A.m Ortiz Bernal, C L Raison, A.m Vargas Prieto et al.
5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT) is a potent, short-acting psychedelic compound found in several South American plant species and in the glandular secretions of Incilius alvarius, a toad native to the Sonoran Desert. While plant-based snuff preparations containing 5-MeO-DMT have documented use in Indigenous Caribbean and South American contexts, recent claims that toad-derived...